Logo

Alytas Therapeutics Signs an Agreement with Velabs Therapeutics to Develop Novel Immune-Based Therapy for Obesity

Share this

Alytas Therapeutics Signs an Agreement with Velabs Therapeutics to Develop Novel Immune-Based Therapy for Obesity

Shots:

  • Velabs and Alytas collaborated to jointly develop modulatory and functional Ab for a novel immune-based therapy against obesity utilizing Velabs' microfluidic-based technology for rapid functional antibody screening
  • Velabs to receive royalties on the global sales of the products resulting from the collaboration. The collaboration focuses to develop a new treatment for obesity to reduce the global increase in associated co-morbidities such as diabetes and cardiovascular disease
  • Velab’s microfluidic technology tests millions of correctly paired human and mouse IgGs for therapeutic effects and is used for the screening of Ab with modulatory function on complex signaling proteins

Click here to­ read full press release/ article | Ref: Velabs Therapeutics | Image: Alytas Therapeutics


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions